"Welcoming the New Spring, Planning Development, Starting the Journey" Jiangxi Pharmaceutical Industry Association 2023 Annual Meeting and Spring Symposium Grandly Held

Dragon soaring across the four seas, a new journey begins. To further strengthen the organizational construction of Jiangxi Province's pharmaceutical industry and better play the association's roles of "service, bridge, link, rights protection, and self-discipline," the Jiangxi Pharmaceutical Industry Association's 2023 Annual Meeting and Spring Symposium was grandly held on the morning of March 1 at Nanchang Binjiang Hotel. Representatives of pharmaceutical entrepreneurs from Jiangxi Province gathered together to share friendship, discuss the future, analyze the situation, enjoy achievements, talk about cooperation, seek development, and jointly promote the grand plan for the development of the pharmaceutical and health industry.

The meeting was chaired by Chen Niandai, President of the Jiangxi Pharmaceutical Industry Association and Chairman of Jiangxi Huiren Pharmaceutical Holdings Co., Ltd. Attendees included Xiong Yan, Second-level Researcher of the Pharmaceutical Industry Department of Jiangxi Provincial Department of Industry and Information Technology; Zhang Jingsheng, Vice President of the Jiangxi Pharmaceutical Industry Association, Party Secretary and Chairman of Jiangxi Sanghai Group; Wang Yaohui, Secretary-General of the Jiangxi Pharmaceutical Industry Association; and more than 70 leaders from member units of the association.

President Chen Niandai pointed out that the Jiangxi Pharmaceutical Industry Association has been established for 20 years. With the care and support of government departments at all levels, leaders, and all sectors of society, the association has focused on innovative pharmaceutical development, built platforms, integrated resources, and strived to play a good bridging role between the government and enterprises. The association's organizational structure has become increasingly complete, service models more mature, and the pharmaceutical industry has moved towards standardized and orderly development. Member units focus on key technologies, closely align with clinical needs, market demand-oriented, driven by technological innovation, each leveraging their own advantages, working together, and integrating development to contribute to the high-quality development of the province's pharmaceutical industry. President Chen emphasized that we must keep pace with the times, actively change our mindset, embrace the development trends of the digital economy and artificial intelligence, accelerate the digital transformation of the pharmaceutical industry, improve the levels of high-end, intelligent, and green development, and cultivate new momentum, promote new development, and create new brilliance for the high-quality development of Jiangxi's pharmaceutical industry.

At the meeting, Xiong Yan, Second-level Researcher of the Pharmaceutical Industry Department of the Provincial Department of Industry and Information Technology, reported on the operation of the province's pharmaceutical industry in 2023 and interpreted relevant government policies. Xiong Yan stated that our province's pharmaceutical industry is resilient, has great potential, and is vibrant. We should rely on Jiangxi's obvious advantages in biopharmaceutical industry technology, research and development, and market to accelerate the creation of a competitive biopharmaceutical industry cluster. It is required to strengthen the leading role of enterprises in scientific and technological innovation, increase R&D investment, vigorously apply for pharmaceutical innovation and R&D projects, and precisely empower the high-quality development of our province's pharmaceutical industry. Vice President Zhang Jingsheng reported on the association's financial income and expenditure in 2023, promising to continue ensuring financial transparency and compliance, optimize resource allocation, and serve member units. Secretary-General Wang Yaohui reported on the association's work in 2023 and plans for 2024. He stated that in 2023, with the joint efforts of all member units, the provincial pharmaceutical industry association closely focused on the development goals of Jiangxi's pharmaceutical industry, actively played the role of bridge and link, committed to being a good assistant to the government and helper to members, and made due contributions to promoting the high-quality development of the province's pharmaceutical industry. In 2024, the association will adhere to the work ideas of serving government decision-making, serving industry development, and serving member development, further stimulating the vitality of Jiangxi's pharmaceutical industry, boosting confidence, and improving the levels of industrial digitalization, intelligence, and greenness. It will continue to carry out policy promotion and interpretation in the pharmaceutical industry field, actively organize exchanges and discussions on industry pain points and difficulties, strive to build a platform for communication and sharing among member units, and create conditions for member enterprises to participate in industry activities.

At the meeting, leaders from Jiangxi Biological Products Research Co., Ltd., Jiangxi Luyan Pharmaceutical Co., Ltd., Jiangxi Yiyou Pharmaceutical Co., Ltd., Nanchang Shikong Yueke Technology Co., Ltd., Jiangxi Xinglin Baima Pharmaceutical Co., Ltd., Nanchang Hongyi Pharmaceutical Technology Co., Ltd., Jiangxi Yintao Pharmaceutical Co., Ltd., China National Pharmaceutical Group Jiangxi Branch, and Zhangshu Pharmaceutical Commerce Association actively spoke, exchanging views on difficulties and hot issues in the pharmaceutical industry. They put forward constructive opinions on pharmaceutical compliance, pharmaceutical industry chain, supply chain development, enterprise resource sharing, enterprise transformation and upgrading, innovative R&D projects, policy guidance, and other aspects. The attending representatives unanimously hoped that the association could continue to play a good bridging role, actively reflect industry demands to relevant government departments, formulate policies and measures to support industry development, and promote the high-quality development of pharmaceutical enterprises in our province. (This article is reprinted from the "Hongyi Pharmaceutical" WeChat public account)